BridgeBio Pharma (BBIO) Other Non Operating Income (2018 - 2025)

BridgeBio Pharma's Other Non Operating Income history runs 8 years deep, the most recent figure standing at $11.8 million for Q4 2025.

• In Q4 2025, Other Non Operating Income changed N/A year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $18.4 million (up 123.13% YoY), while the FY2025 annual figure was $43.1 million, up 261.93% from the prior year.
• Other Non Operating Income came in at $11.8 million for Q4 2025 at BridgeBio Pharma, up from $6.5 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $28.3 million in Q4 2021 to a low of -$10.8 million in Q2 2022.
• A 5-year average of $5.4 million and a median of $5.8 million in 2021 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income tumbled 7700.0% in 2021 and surged 1677.87% in 2024, its largest moves.
• BridgeBio Pharma's Other Non Operating Income stood at $28.3 million in 2021, then plunged by 83.88% to $4.6 million in 2022, then soared by 377.59% to $21.8 million in 2023, then slumped by 56.46% to $9.5 million in 2024, then gained by 24.62% to $11.8 million in 2025.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $11.8 million, $6.5 million, and $8.2 million for Q4 2025, Q2 2025, and Q1 2025 respectively.

Peer Comparison